| Catalyzed by the epidemic,my country’s pharmaceutical manufacturing industry will maintain rapid growth in 2021,and the growth rate is 6.4 and 15.2 percentage points higher than that of high-tech manufacturing and the national industry,respectively.As one of the industries with the highest technology content,the pharmaceutical manufacturing industry must continue to invest in new drugs.In order to improve the competitiveness of the pharmaceutical manufacturing industry,the overall innovation capability and R&D level of the industry can be improved.my country’s innovative drug market accounts for a small proportion,and the transformation rate of scientific research results is low.The industry itself has the disadvantages of high long-term R&D pressure and short-term production costs.conditions,which requires enterprises to formulate scientific and effective R&D strategies to enhance their core competitiveness.In order to promote the research and development of the pharmaceutical industry,the state has also introduced a series of relevant policies such as "4+7" volume procurement,priority review system and generic drug consistency evaluation.The dual incentives of the state and the market have enabled the Chinese pharmaceutical industry to enter a new outlet for innovation and development.Based on the current problems of high difficulty and risk in Hengrui’s R&D,this paper discusses the next R&D strategy trend of Hengrui’s medicine in combination with enterprise performance evaluation.This paper first analyzes the external environment and internal environment of Hengrui Pharmaceutical,analyzes the current policy environment,economic environment,social and cultural environment,technical environment and industry environment of Hengrui Pharmaceutical,and understands the market and environmental status quo faced by Hengrui Pharmaceutical.It focuses on the internal environment of Hengrui Pharmaceutical,and finds that Hengrui’s continuous investment in R&D and innovation has continuously enhanced the independent R&D capability of enterprises,At the same time,it has obtained a large number of invention patents and intangible assets and other technical resources.Secondly,the impact of R&D investment on the financial performance and non-financial performance of the company is analyzed,and then it is found that the financial performance of Hengrui Pharmaceutical is delayed compared with the R&D investment,and it has made significant achievements in non-performance;From the perspective of investors,Hengrui Pharmaceutical’s increasing R&D had a good market reaction.Based on the existing problems in the R&D of Hengrui Pharmaceutical,the R&D strategy was improved and formulated.The strategy was put forward from the dimensions of human resources measures,R&D related measures,financial management measures,etc.,and the human resources measures of Hengrui Pharmaceutical to recruit talents globally and establish a reasonable R&D system to retain R&D personnel were determined.The overall R&D strategy of enterprises to improve the transformation rate of R&D achievements,increase R&D efforts and break through the international level was clarified.Finally,in terms of financial management measures,we will build the R&D risk assessment system,R&D resource layout,and tracking the sustainable benefits of R&D projects to make these three dimensions of strategic measures complement each other,form the core competitiveness of enterprises,and thus improve enterprise performance.This paper plays a role in the case study of Hengrui Pharmaceutical’s R&D investment and enterprise performance,helping to strengthen the emphasis of pharmaceutical enterprises on R&D investment,and providing reference for the formulation and implementation of pharmaceutical enterprises’ R&D strategies. |
PDF Full Text Request